Impact of Delta Variant Being Overanalyzed
Insights - The Covid delta variant is making waves, and several countries are voicing concern. Below we look at the data and determine if the high alert … Continue Reading
PremiumMust Read
Obesity & PD-1: History Doesn’t Repeat But It Rhymes
The early innings of the obesity landscape is starting to take shape, and it seems to be forming similar patterns...
Read NowModular Medical Submits 510(k) for Insulin Patch Pump
Modular Medical (MODD) announced the 510(k) submission of their MODD1 insulin pump to the FDA last week. On average, the FDA takes approximately...
PremiumLatest Posts
FDA Places Magenta’s ADC Conditioning Program On Hold
Insights - Magenta announced that the FDA has placed a clinical hold on their IND filed in June 2021 for conditioning agent MGTA-117. As a result, MGTA will need … Continue Reading
Premium
Eloxx To Present CF Data in Early Q4 2021
Insights - Yesterday, Eloxx (ELOX) was down 17% to $1.60 after the company provided an enrolment update for ELX-02 Phase 2 in cystic fibrosis. The company expects to present … Continue Reading
Premium
Genentech Discontinues Affimed’s BCMA Candidate
Insights - Affimed had the Q1 business update call this morning. The call was not well received after the company did not shed much light on AFM24 progress and … Continue Reading
Premium
Jounce R&D Day 2021 Focuses on LILRB Family
Insights - Last week, Jounce hosted their R&D day to update investors on their pipeline and future prospects (watch webinar here). Overall, we thought the company provided good … Continue Reading
PremiumEloxx Risk-Reward Compelling Ahead of Cystic Fibrosis Data
Research - Eloxx (ELOX) is developing a cystic fibrosis treatment for the 12% of patients that Vertex’s therapies cannot treat. The mechanism of action in the ribosome … Continue Reading
PremiumJounce Hands Over CCR8 Clinical Development To Gilead
Insights - Earlier this week Jounce (JNCE) received a $25M milestone payment from Gilead (GILD) for advancing their anti-CCR8 antibody through IND clearance. Gilead will now develop this program, … Continue Reading
Premium